Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and <i>HER2</i>-Mutated Breast Cancer

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and <i>HER2</i>-Mutated Breast Cancer

An estimated 15&#8722;20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and neratinib, have been approved for the treatment of HER2-positive (HER2+) breast cancer. Lapatinib, a reversible e...

Full description

Bibliographic Details
Main Authors: Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, John Crown
Format: Article
Language:English
Published: MDPI AG 2019-05-01
Series:Cancers
Subjects:
tyrosine kinase inhibitors
lapatinib
neratinib
HER2
breast cancer
Online Access:https://www.mdpi.com/2072-6694/11/6/737

Internet

https://www.mdpi.com/2072-6694/11/6/737

Similar Items